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Abstract
Background: Poor recruitment in clinical trials is well-documented. In large, multi-centre trials, communication
between the coordinating centre and trial sites is essential. A commonly used communication tool is the hosting of
an investigator/collaborator meeting, which offers an opportunity for sites to re-train and receive trial updates, learn
from each other, share best practice and troubleshoot issues. Anecdotally, there is a perception that recruitment
rates may increase after holding such a meeting. The aim of this before-and-after study was to examine any
changes in recruitment after an investigator meeting.
Methods: We conducted a retrospective study of nine trials at the Nottingham Clinical Trials Unit (NCTU) that were
open to recruitment between 2014 and 2018. In the 8 weeks prior to the date of the investigator meeting, 82 sites
(across nine trials) were open to recruitment; 60 of which attended the meeting, 22 who did not. Using meeting
attendance data available in Trial Master Files (TMF) and recruitment data from randomisation datasets, we
examined recruitment rates in the 8 weeks prior to and following the date of the investigator meeting.
Results: For the 82 sites included, 284 participants were recruited in the 8 weeks prior to the meeting, with a
further 300 participants recruited in the 8 weeks post meeting. This gives a mean change in weekly recruitment of
0.073 (− 0.129, 0.275) per site, demonstrating no statistically significant increase in recruitment after the investigator
meeting. For the 60 attending sites, recruitment increased from 254 participants prior to the meeting to 271 post
meeting, giving a 0.100 (− 0.160, 0.360) mean change in weekly recruitment per site, providing no evidence that
recruitment rates increase following an investigator meeting.
Conclusion: There is no statistical evidence to conclude that holding an investigator meeting increases recruitment
in the 8 weeks following the meeting. Thus, if the meeting has been held in the belief that it will have a positive
impact upon recruitment, trialists may wish to consider other evidence-based strategies known to increase
recruitment rates. However, since there are a variety of reasons why an investigator meeting may be held, trialists
should continue to consider this as a communication strategy with sites.
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Background
Clinical trials often fail to recruit to time and on target,
and issues with poor recruitment are well-documented
[1]. To run a successful trial that adequately answers the
research question, a large collaborative team is required,
particularly for definitive trials. It is important to ensure
continued communication with trial sites throughout
and, although there has been no formal evaluation, it is
thought that good communication with sites could have
an effect upon trial recruitment [2, 3]. Groups such as
the Hubs for Trials Methodology Research (HTMR) rec-
ommend maintaining engagement with clinical trial sites
and holding meetings as a strategy that may improve re-
cruitment [4]. It is commonplace for trials to hold meet-
ings with site staff, such as the principal investigator and
research nurse, who are responsible for recruitment of
participants and data collection. These are often known
as ‘investigator’ or ‘collaborator’ meetings. Indeed, some
Clinical Trials Units (CTUs) include the costs for such
meetings in funding applications and these meetings
form part of their standard practices. Such meetings can
be held during the recruitment and data-collection phase
of a trial, and are often repeated intermittently for the
duration of a trial. In some circumstances, the meetings
may be held in response to trial-specific issues, such as
poor recruitment. They offer an opportunity for sites to
re-train, network and be part of the trial community and
to share good practice or troubleshoot issues with other
sites and the coordinating centre. At least anecdotally,
there appears to be a belief amongst trialists that holding
an investigator meeting may lead to an increase in re-
cruitment. However, after searching a range of resources,
including the Online Resource for Recruitment Research
in Clinical Trials (ORRCA) [5], Trial Forge [6] and the
Study Within a Trial (SWAT) repository store on the
Northern Ireland Hub for Trials Methodology Research
[7], along with literature searches, we found no pub-
lished evidence to support this. The aim of this study
was to examine whether holding an investigator meeting
in multi-centre trials, managed by the Nottingham Clin-
ical Trials Unit (NCTU), had an impact on trial
recruitment.
Methods
Using data available in Trial Master Files (TMFs) and
trial recruitment data, we conducted a retrospective re-
view of multi-centre trials from NCTU’s portfolio of tri-
als over a 5-year period between January 2014 and
December 2018. Trials that met the following criteria
were included in data collection and analysis: (1) more
than one site, i.e. multi-centre, (2) in the recruitment
phase during the selected time period, (3) held at least
one face-to-face investigator meeting during the recruit-
ment period and (4) unit of randomisation was
individual participants (any trials that included group
randomisation were not included). During the selected
time period, NCTU had two group-based therapy trials
where groups of participants were randomised, rather
than individuals. It was agreed these should not be in-
cluded since recruitment issues and strategies may vary
substantially from trials where individual participants are
recruited. We defined an investigator meeting as a meet-
ing where all participating United Kingdom (UK) sites
were invited to attend to hear trial updates, share infor-
mation and discuss issues, in accordance with the stand-
ard operating procedure at the NCTU. Trials that held
smaller, local or regional meetings or only held meetings
for a different purpose (i.e. to discuss study results) were
not included. A simple data-collection tool using JISC
online surveys© was designed to collect basic details re-
lating to any investigator meetings held during the re-
cruitment phase of the trial. This included the
characteristics of each trial, when the meeting(s) were
held, which sites were in attendance and which type of
site staff (i.e. job role) attended the meeting(s). The data-
collection tool was user-tested by the authors and circu-
lated to trial management staff for completion. Recruit-
ment data for each site for the 8 weeks pre and post
investigator meeting were taken directly from the ran-
domisation datasets for each trial. Although somewhat
arbitrary, this time period was selected to ensure that
the maximum amount of recruitment data could be in-
cluded from the studies involved and seemed an appro-
priate length of time that a potential effect on
recruitment levels may be seen. We felt that if an effect
was seen on recruitment > 8 weeks after the investigator
meeting, it would be less plausible to suggest an associ-
ation between the two.
For trials that held more than one meeting during the
recruitment period, we used data from the meeting that
was held closest to the middle of the recruitment period.
The rationale for this was that meetings held towards
the middle of the recruitment period should involve the
largest number of sites open to recruitment, rather than
meetings held towards the start of the period that may
involve only a small number of actively recruiting sites
or towards the end of a trial when sites may have closed
to recruitment or reached their recruitment target.
Statistical analysis
Continuous variables were summarised with mean and
standard deviation (SD), or median and interquartile
range (IQR). Categorical variables were described with
frequency counts and percentages. Linear mixed-effects
models were fitted with 16 weeks of recruitment data
per site to estimate the change in recruitment after an
investigator meeting with the following data structure:
weeks nested within sites, with sites nested within trials.
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One model was fitted for all eligible sites, and a second
only for sites who attended their investigator meeting. In
both models, random intercepts were fitted at both trial
and site level. The assumptions of the models were
checked to ensure that the residuals were normally dis-
tributed, the variance was homogenous and that there
was a linear relationship between the residuals and pre-
dictor. All analyses were performed in Stata version 16.0
or later.
Results
During the 5-year selected time period, there were a
total of 20 trials managed by NCTU. Eleven of these did
not meet our pre-specified eligibility criteria, with four
not open to recruitment during the study period (4/11,
36%), five that did not hold an investigator meeting dur-
ing the study period (5/11, 45%) and two that used
group randomisation (2/11, 18%). Thus, nine trials were
included in this study; all of which have been published
or have published protocols [8–16]. One trial, the Leu-
copatch trial, included a small number of international
sites (n = 10) though for consistency purposes it was felt
better to only include data relating to UK sites. In total
the trials comprised a total of 120 UK sites, however, 38
of these were not open to recruitment at least 8 weeks
prior to the investigator meeting and, thus, these sites
were not included. Eighty-two sites were open to
recruitment at least 8 weeks before the investigator
meeting, of which 60 attended the meeting and 22 did
not (Fig. 1).
Characteristics of the included trials are shown in
Table 1. The nine trials included a range of Clinical Tri-
als of Investigational Medicinal Products (CTIMPs), de-
vice trials and complex intervention trials. Six trials were
the definitive main trial and three were feasibility trials.
Most (8/9, 88.9%) were funded by the National Institute
for Health Research (NIHR). Trials spanned several clin-
ical areas including dermatology (3/9), pregnancy and
childbirth (2/9), diabetes (1/9), gastroenterology (1/9),
hand surgery (1/9) and sexual health (1/9). Six trials re-
cruited adults only, two were paediatric and one re-
cruited both adults and children. The mean sample size
was 549.6 participants (SD 648.6, range 50–1900) and
involved, on average, 14 sites (SD 8.1, range 3–25). The
mean length of recruitment time was 23.6 months (SD
11.7, range 10–44.4).
Investigator meetings were conducted throughout the
calendar year, spanning all seasons. On average, there
were eight sites open to recruitment for at least 8 weeks
prior to the investigator meeting per trial (median 8,
IQR 8–12) with seven who actually attended the meeting
(median 7, IQR 7–8). For the 60 sites who attended the
investigator meeting for their trial, on average two mem-
bers of site staff were in attendance. It was more com-
mon for research nurses/midwives (n = 62, 84%) and
Fig. 1 Flow diagram showing included and excluded trials
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principal investigators (36, 49%) to attend, though other
roles also in attendance included co-investigators, bio-
medical scientists, research assistants and microbiolo-
gists; this varied for each trial.
The effect of an investigator meeting upon 8-weekly
recruitment is given in Table 2. Irrespective of attend-
ance at the investigator meeting, for the 82 sites from
the nine trials included, a total of 284 participants were
recruited in the 8 weeks prior to the investigator meeting
being held, with 300 participants recruited in the 8
weeks following the meeting. The mean change in
weekly recruitment per site was 0.073 (95% confidence
interval (CI) − 0.129, 0.275). This translates to recruit-
ment of one extra participant per 14 sites per week.
For the 60 sites who attended the investigator meeting,
a total of 254 participants were recruited in the 8 weeks
prior to the day of the meeting, with 271 participants re-
cruited in the 8 weeks after the investigator meeting.
The mean change in weekly recruitment per site was
0.100 (95% CI − 0.160, 0.360), translating into the re-
cruitment of one extra participant per 10 sites per week.
For the 22 sites who did not attend the investigator
meeting, a total of 30 participants were recruited in the
8 weeks prior to the meeting and 29 in the 8 weeks after
the meeting, giving a mean change in weekly recruit-
ment per site of 0.00 (95% CI − 0.236, 0.236). The
change in recruitment rates before and after the investi-
gator meeting, for all sites, are shown in Fig. 2 and the
differences between attending and non-attending sites
are shown in Fig. 3.
Discussion
In this small retrospective study, there was no evidence
to suggest that holding an investigator meeting may in-
crease recruitment in the 8 weeks following the meeting.
Although recruitment of one extra participant per week
per 14 sites is a modest increase, the variability around
this estimate was high such that this finding may have
been due to chance.
Although the aim of this study was to investigate
whether holding an investigator meeting improved re-
cruitment rates overall, we did undertake additional ex-
ploratory analyses to examine any differences between
sites who were able to attend the meeting and those
Table 1 Characteristics of included trials
Characteristic Trials (n = 9) (%)
Type of trial
CTIMP 3 (33%)
Device 1 (11%)
Intervention 5 (56%)
Stage of trial
Definitive 6 (67%)
Feasibility 3 (33%)
Funding type
NIHR 8 (89%)
Industry 1 (11%)
Clinical area
Dermatology 3 (33%)
Diabetes 1 (11%)
Gastroenterology 1 (11%)
Hand surgery 1 (11%)
Pregnancy and childbirth 2 (22%)
Sexual health 1 (11%)
Population
Adults 6 (67%)
Paediatric 2 (22%)
Adults and paediatric 1 (11%)
Sample size
Mean (SD) 549.6 (648.6)
Median (IQR) 269 (180, 517)
Min, Max 50, 1900
Length of recruitment (months)
Mean (SD) 23.6 (11.7)
Median (IQR) 22.4 (17.1, 26.1)
Min, Max 10.0, 44.4
Number of sitesa
Mean (SD) 13.9 (8.1)
Median (IQR) 16 (8, 22)
Min, Max 3, 25
All data are N (%) unless otherwise stated
CTIMP Clinical Trial of an Investigational Medicinal Product, IQR interquartile
range, NIHR National Institute for Health Research (any programme)
aOne trial was international and for this study only the UK sites are included
Table 2 Effect of investigator meeting on weekly recruitment rate 8 weeks pre and post meeting – results from linear mixed-effects
models
Population Time point 8-weekly recruitment Mean change in weekly recruitment per site (95% CI) P valuea
All sites (n = 82) Pre meeting 284 0.073 (− 0.129, 0.275) 0.48
Post meeting 300
Sites who attended (n = 60) Pre meeting 254 0.100 (− 0.160, 0.360) 0.45
Post meeting 271
CI confidence interval
ap values are from a Wald chi-square test with one degree of freedom
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who were not. Our data suggests that for sites who at-
tend the meeting, there is a small non-significant in-
crease in recruitment in comparison to non-attending
sites, where there is no increase in recruitment after the
meeting. Unsurprisingly, the sites who did not attend
the meeting had lower recruitment rates, before and
after the investigator meeting, than the sites who
attended. This could suggest that the sites who attended
the meeting had a higher level of engagement in the trial
and that if recruitment is a primary concern, an investi-
gator meeting might not be effective in reaching the
target audience. It is, however, impossible to know if this
was the case retrospectively.
Although there is no evidence to suggest a statistically
significant increase in recruitment after an investigator
meeting, nor does this data suggest a decrease in recruit-
ment. As previously described, investigator meetings are
often held for a variety of reasons and, thus, we are not
suggesting that since this data supports no evidence of
an increase in recruitment rates, you should not con-
sider holding one. For example, you may wish to hold an
investigator meeting for sites to learn from each other
Fig. 2 Change in recruitment rates pre and post investigator meeting (all sites)
Fig. 3 Change in recruitment rates pre and post investigator meeting (attending and non-attending sites)
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and share expertise and, therefore, funding and resource
permitted, it seems sensible to continue to do this.
Whilst no formal qualitative analyses have been under-
taken using feedback and evaluation forms from the
meetings held, all authors recognised that, anecdotally,
site staff often consider attending an investigator meet-
ing to be useful and they enjoy the opportunity to en-
gage with other sites and the team running the trial.
Investigators and trial management staff should, how-
ever, give careful consideration to holding an investiga-
tor meeting purely for the purpose of increasing
recruitment.
To the best of our knowledge, this is the first time that
data has been analysed to examine the effect of holding
an investigator meeting on recruitment rates. This study,
therefore, adds to the evidence base for strategies to im-
prove recruitment into clinical trials. Since holding in-
vestigator meetings is common across many trials,
trialists may want to consider whether their resources be
targeted at evidence-based strategies shown to improve
recruitment rates.
We recognise this study has some limitations. Firstly,
our sample size was small with only nine trials included
during a 5-year period, resulting in just 584 randomisa-
tions recorded during a 16-week period. Thus, it is pos-
sible that a larger study would detect a small but
meaningful recruitment increase in the 8 weeks following
an investigator meeting. Further, a larger study could ex-
plore subgroups of interest, such as time since site initi-
ation with a hypothesis that newly opened sites may not
recruit as quickly as those previously opened, and contain
sufficient numbers of sites to provide a direct statistical
comparison between the recruitment rates for sites who
did and did not attend investigator meetings. Dependent
upon the trials included in a subsequent larger study, con-
sideration may need to be given to other factors, such as
those with a longer screening period, since this may have
a delayed impact upon recruitment rates which would not
be attributable to attendance at an investigator meeting.
Secondly, investigator meetings can be held for a variety
of reasons and we have not attempted to explore the po-
tential effects of holding a meeting on other parameters,
such as data collection and staff involvement and em-
powerment, simply due to the data being unavailable in
this retrospective study. Finally, factors that could influ-
ence site recruitment, such as site engagement and prior
research experience, were not explored, since this data
was not available retrospectively, though we recognise that
a site’s performance is multi-faceted [17] and could influ-
ence recruitment rates.
Conclusion
We found no statistical evidence in our study to con-
clude that holding an investigator meeting increases
recruitment rates in the 8 weeks after the date of the
meeting. Trialists should give careful consideration to
the purpose and use of such meetings in the future.
However, more research could be undertaken to further
explore this. Ideally this would be done prospectively,
though there would be challenges in implementing at-
tendance at an investigator meeting as a SWAT inter-
vention, for example, which may not be seen positively
by trial sites. Nonetheless this study could be expanded
further retrospectively by (1) considering a larger sample
of trials and (2) investigating other outcomes that may
be affected by holding an investigator meeting.
Abbreviations
CTIMPs: Clinical Trials of Investigational Medicinal Products; CTU: Clinical
Trials Unit; NCTU: Nottingham Clinical Trials Unit; NIHR: National Institute for
Health Research; ORRCA: Online Resource for Recruitment Research in
Clinical Trials; SWAT: Study Within a Trial; TMF: Trial Master File
Acknowledgements
We thank the trial managers based at the Nottingham Clinical Trials Unit
who kindly provided data on investigator meetings held for the trials that
they are responsible for.
Authors’ contributions
EJM conceived the idea and wrote the first draft of the manuscript. PJG was
responsible for all analyses. All authors contributed to the study design,
interpretation of results and reviewed and approved the final manuscript.
Funding
PJG was supported by the UK Medical Research Council (MC_UU_12023/24).
Availability of data and materials
The datasets used and analysed during the current study are available from
the corresponding author upon reasonable request.
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Author details
1Nottingham Clinical Trials Unit, University of Nottingham, University Park,
Nottingham, UK. 2MRC Clinical Trials Unit at University College London,
Institute of Clinical Trials and Methodology, London, UK.
Received: 27 January 2020 Accepted: 29 May 2020
References
1. Campbell MK, Snowdon C, Francis D, Elbourne D, McDonald AM, Knight R,
et al. Recruitment to randomised trials: strategies for trial enrollment and
participation study. The STEPS study. Health Technol Assess. 2007;11(48):iii
ix-105.
2. Farrell B, Kenyon S, Shakur H. Managing clinical trials. Trials. 2010;11:78.
3. UK Trial Managers’ Network (UKTMN): a guide to efficient trial management
version 6; 2017 (www.tmn.ac.uk). Accessed 17 Jan 2020.
4. Mills N, Clark M, Young B, Murray G, Williamson P, Donovan J, Bhopal R,
Blazeby J, on behalf of the Recruitment Working Group. HTMR Network
Top-tips for Trial Recruitment, V0.1 July 2013. 2013.
5. Online Resource for Recruitment Research in Clinical Trials (ORRCA): (www.
orrca.org.uk). Accessed 17 Jan 2020.
6. Trial Forge: making trials more efficient (www.trialforge.org). Accessed 17
Jan 2020.
Mitchell et al. Trials          (2020) 21:514 Page 6 of 7
7. The Northern Ireland Hub for Trials Methodology Research SWAT Store
https://www.qub.ac.uk/sites/TheNorthernIrelandNetworkforTrials
MethodologyResearch/SWATSWARInformation/Repositories/SWATStore/.
Accessed 17 Jan 2020.
8. Armstrong-Buisseret L, Brittain C, David M, Dean G, Griffiths F, Hepburn T,
et al. Metronidazole versus lactic acid for treating bacterial vaginosis (VITA):
protocol for a randomised controlled trial to assess the clinical and cost
effectiveness of topical lactic acid gel for treating second and subsequent
episodes of bacterial vaginosis. Trials. 2019;20(1):648.
9. Armstrong-Buisseret L, Mitchell E, Hepburn T, Duley L, Thornton JG, Roberts
TE, et al. Reduced fetal movement intervention Trial-2 (ReMIT-2): protocol
for a pilot randomised controlled trial of standard care informed by the
result of a placental growth factor (PlGF) blood test versus standard care
alone in women presenting with reduced fetal movement at or after 36+ 0
weeks gestation. Trials. 2018;19(1):531.
10. Chalmers JR, Haines RH, Mitchell EJ, Thomas KS, Brown SJ, Ridd M, et al.
Effectiveness and cost-effectiveness of daily all-over-body application of
emollient during the first year of life for preventing atopic eczema in high-
risk children (The BEEP trial): protocol for a randomised controlled trial.
Trials. 2017;18(1):343.
11. Duley L, Dorling J, Pushpa-Rajah A, Oddie SJ, Yoxall CW, Schoonakker B,
et al. Randomised trial of cord clamping and initial stabilisation at very
preterm birth. Arch Dis Child Fetal Neonatal Ed. 2018;103(1):F6–F14.
12. Game F, Jeffcoate W, Tarnow L, Jacobsen JL, Whitham DJ, Harrison EF, et al.
LeucoPatch system for the management of hard-to-heal diabetic foot ulcers
in the UK, Denmark, and Sweden: an observer-masked, randomised
controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):870–8.
13. Haines RH, Thomas KS, Montgomery AA, Ravenscroft JC, Akram P, Chalmers
JR, et al. Home interventions and light therapy for the treatment of vitiligo
(HI-Light Vitiligo Trial): study protocol for a randomised controlled trial. BMJ
Open. 2018;8(4):e018649.
14. Harrison E, Tan W, Mills N, Karantana A, Sprange K, Duley L, et al. A
feasibility study investigating the acceptability and design of a multicentre
randomised controlled trial of needle fasciotomy versus limited fasciectomy
for the treatment of Dupuytren's contractures of the fingers (HAND-1):
study protocol for a randomised controlled trial. Trials. 2017;18(1):392.
15. Major G, Bradshaw L, Boota N, Sprange K, Diggle M, Montgomery A, et al.
Follow-on RifAximin for the Prevention of recurrence following standard
treatment of Infection with Clostridium Difficile (RAPID): a randomised
placebo controlled trial. Gut. 2019;68(7):1224–31.
16. Thomas KS, Bradshaw LE, Sach TH, Batchelor JM, Lawton S, Harrison EF,
et al. Silk garments plus standard care compared with standard care for
treating eczema in children: a randomised, controlled, observer-blind,
pragmatic trial (CLOTHES Trial). PLoS Med. 2017;14(4):e1002280.
17. Whitham D, Turzanski J, Bradshaw L, Clarke M, Culliford L, Duley L, et al.
Development of a standardised set of metrics for monitoring site
performance in multicentre randomised trials: a Delphi study. Trials. 2018;
19(1):557.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Mitchell et al. Trials          (2020) 21:514 Page 7 of 7
